| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalomyelitis, Autoimmune, Experimental | 34 | 2024 | 55 | 7.200 |
Why?
|
| Multiple Sclerosis | 23 | 2024 | 50 | 5.680 |
Why?
|
| Autoimmune Diseases | 9 | 2024 | 65 | 2.430 |
Why?
|
| Peptide Fragments | 19 | 2021 | 307 | 2.090 |
Why?
|
| T-Lymphocytes | 19 | 2025 | 386 | 1.970 |
Why?
|
| Pertussis Toxin | 9 | 2013 | 25 | 1.800 |
Why?
|
| Th1 Cells | 15 | 2018 | 97 | 1.780 |
Why?
|
| Lymphocyte Activation | 15 | 2021 | 249 | 1.720 |
Why?
|
| Mice, Transgenic | 21 | 2024 | 665 | 1.670 |
Why?
|
| Myelin Proteolipid Protein | 8 | 2021 | 12 | 1.520 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 5 | 2025 | 9 | 1.500 |
Why?
|
| Adjuvants, Immunologic | 6 | 2021 | 117 | 1.490 |
Why?
|
| T-Lymphocyte Subsets | 10 | 2014 | 91 | 1.460 |
Why?
|
| Inflammation | 6 | 2025 | 758 | 1.450 |
Why?
|
| Cytokines | 15 | 2016 | 678 | 1.440 |
Why?
|
| Mice | 67 | 2025 | 6644 | 1.370 |
Why?
|
| Animals | 83 | 2025 | 16992 | 1.340 |
Why?
|
| Central Nervous System | 9 | 2021 | 152 | 1.310 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2020 | 279 | 1.260 |
Why?
|
| Interferon-gamma | 16 | 2016 | 269 | 1.140 |
Why?
|
| HLA Antigens | 3 | 2025 | 27 | 1.120 |
Why?
|
| Th2 Cells | 11 | 2014 | 62 | 1.110 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 1596 | 1.070 |
Why?
|
| HLA-DR4 Antigen | 7 | 2018 | 21 | 1.070 |
Why?
|
| HLA-DR2 Antigen | 3 | 2018 | 4 | 1.040 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2025 | 11 | 1.030 |
Why?
|
| Mice, Inbred C57BL | 29 | 2024 | 1869 | 1.030 |
Why?
|
| Epitopes, T-Lymphocyte | 13 | 2013 | 60 | 1.010 |
Why?
|
| Freund's Adjuvant | 10 | 2021 | 14 | 1.010 |
Why?
|
| Antigen Presentation | 8 | 2021 | 58 | 0.980 |
Why?
|
| Immunologic Memory | 7 | 2020 | 42 | 0.870 |
Why?
|
| Autoimmunity | 10 | 2024 | 58 | 0.870 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 65 | 0.840 |
Why?
|
| Myelin-Associated Glycoprotein | 6 | 2011 | 9 | 0.830 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2019 | 2 | 0.780 |
Why?
|
| Quorum Sensing | 1 | 2022 | 16 | 0.750 |
Why?
|
| Astrocytes | 2 | 2019 | 244 | 0.740 |
Why?
|
| Lipids | 5 | 2014 | 256 | 0.730 |
Why?
|
| Cell Wall | 2 | 2021 | 55 | 0.720 |
Why?
|
| Capsules | 1 | 2021 | 28 | 0.690 |
Why?
|
| Humans | 52 | 2025 | 43102 | 0.680 |
Why?
|
| Proteoglycans | 1 | 2021 | 49 | 0.680 |
Why?
|
| Myeloid Cells | 3 | 2021 | 31 | 0.680 |
Why?
|
| Antigen-Presenting Cells | 7 | 2015 | 31 | 0.640 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 12 | 0.630 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2021 | 199 | 0.620 |
Why?
|
| Brain Neoplasms | 3 | 2025 | 140 | 0.610 |
Why?
|
| Bacteria | 1 | 2022 | 293 | 0.600 |
Why?
|
| Antigens | 3 | 2018 | 59 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 306 | 0.590 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 15 | 0.580 |
Why?
|
| Neuroglia | 1 | 2019 | 133 | 0.550 |
Why?
|
| Neuromyelitis Optica | 3 | 2024 | 3 | 0.530 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 30 | 0.530 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2025 | 69 | 0.530 |
Why?
|
| HLA-DR Antigens | 6 | 2011 | 23 | 0.530 |
Why?
|
| Cell Differentiation | 5 | 2020 | 638 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2009 | 105 | 0.520 |
Why?
|
| Cell Lineage | 2 | 2020 | 104 | 0.510 |
Why?
|
| Francisella tularensis | 6 | 2016 | 116 | 0.490 |
Why?
|
| Spinal Cord | 3 | 2013 | 114 | 0.470 |
Why?
|
| Proteomics | 6 | 2021 | 378 | 0.460 |
Why?
|
| Myelin Sheath | 1 | 2015 | 46 | 0.460 |
Why?
|
| Bacterial Vaccines | 7 | 2016 | 129 | 0.460 |
Why?
|
| Cells, Cultured | 12 | 2021 | 1621 | 0.460 |
Why?
|
| Interleukin-17 | 5 | 2016 | 53 | 0.450 |
Why?
|
| Antigens, Neoplasm | 4 | 2025 | 90 | 0.450 |
Why?
|
| Lipid Peroxidation | 1 | 2015 | 140 | 0.450 |
Why?
|
| Mice, Knockout | 13 | 2018 | 1035 | 0.450 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 14 | 0.440 |
Why?
|
| Body Fluids | 1 | 2014 | 19 | 0.440 |
Why?
|
| Immunotherapy | 3 | 2025 | 144 | 0.440 |
Why?
|
| Glioblastoma | 2 | 2025 | 74 | 0.430 |
Why?
|
| Female | 41 | 2025 | 24698 | 0.420 |
Why?
|
| Mast Cells | 5 | 2013 | 82 | 0.420 |
Why?
|
| Chlamydia Infections | 6 | 2013 | 200 | 0.410 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 148 | 0.400 |
Why?
|
| Transcription Factors | 1 | 2018 | 735 | 0.400 |
Why?
|
| Chlamydia muridarum | 6 | 2013 | 104 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2011 | 184 | 0.380 |
Why?
|
| Mice, Inbred Strains | 8 | 2013 | 114 | 0.370 |
Why?
|
| Proteins | 1 | 2014 | 382 | 0.360 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2002 | 5 | 0.360 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2009 | 108 | 0.350 |
Why?
|
| Thymus Gland | 2 | 2009 | 76 | 0.350 |
Why?
|
| Neurons | 1 | 2019 | 1263 | 0.350 |
Why?
|
| T-Box Domain Proteins | 1 | 2011 | 7 | 0.340 |
Why?
|
| Integrin alpha4beta1 | 1 | 2011 | 5 | 0.340 |
Why?
|
| Anaphylaxis | 1 | 2011 | 15 | 0.340 |
Why?
|
| Mice, Inbred BALB C | 14 | 2016 | 694 | 0.320 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1271 | 0.320 |
Why?
|
| Interleukin-4 | 6 | 2012 | 75 | 0.320 |
Why?
|
| Autoantibodies | 4 | 2024 | 117 | 0.310 |
Why?
|
| Proteome | 4 | 2017 | 152 | 0.300 |
Why?
|
| Immunization | 6 | 2013 | 94 | 0.290 |
Why?
|
| Immune Tolerance | 6 | 2008 | 68 | 0.290 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2025 | 30 | 0.290 |
Why?
|
| MicroRNAs | 1 | 2014 | 518 | 0.290 |
Why?
|
| Alternative Splicing | 2 | 2025 | 94 | 0.280 |
Why?
|
| Cell Movement | 5 | 2013 | 655 | 0.280 |
Why?
|
| Myelin Proteins | 6 | 2011 | 18 | 0.270 |
Why?
|
| Tularemia | 6 | 2016 | 115 | 0.270 |
Why?
|
| Epitopes | 4 | 2025 | 157 | 0.260 |
Why?
|
| Apoptosis | 3 | 2015 | 1568 | 0.250 |
Why?
|
| Brain | 3 | 2013 | 1472 | 0.250 |
Why?
|
| Neoplasms | 1 | 2017 | 1377 | 0.250 |
Why?
|
| Adoptive Transfer | 5 | 2013 | 53 | 0.240 |
Why?
|
| Cell Survival | 1 | 2009 | 945 | 0.240 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2025 | 8 | 0.240 |
Why?
|
| Animals, Newborn | 5 | 2010 | 352 | 0.240 |
Why?
|
| Genital Diseases, Female | 3 | 2011 | 38 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2025 | 11 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2025 | 32 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2022 | 2157 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2021 | 165 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 83 | 0.220 |
Why?
|
| Injections, Intraperitoneal | 5 | 2013 | 60 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2025 | 200 | 0.220 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 206 | 0.210 |
Why?
|
| Glioma | 1 | 2025 | 96 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 32 | 0.210 |
Why?
|
| Antigens, Bacterial | 3 | 2010 | 144 | 0.210 |
Why?
|
| Immunodominant Epitopes | 5 | 2012 | 29 | 0.210 |
Why?
|
| Suramin | 1 | 2004 | 4 | 0.210 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 59 | 0.200 |
Why?
|
| Transcription, Genetic | 2 | 2025 | 592 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 384 | 0.190 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 189 | 0.190 |
Why?
|
| Receptors, Cytokine | 2 | 2013 | 11 | 0.190 |
Why?
|
| Immune System | 1 | 2022 | 41 | 0.190 |
Why?
|
| Cross Infection | 1 | 2022 | 48 | 0.190 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 40 | 0.190 |
Why?
|
| Cell Count | 1 | 2022 | 145 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2024 | 213 | 0.180 |
Why?
|
| Autoantigens | 7 | 2005 | 87 | 0.180 |
Why?
|
| Mammals | 1 | 2022 | 112 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2015 | 411 | 0.180 |
Why?
|
| Integrin alpha4 | 1 | 2021 | 2 | 0.170 |
Why?
|
| Serum Amyloid A Protein | 1 | 2021 | 14 | 0.170 |
Why?
|
| Incidence | 2 | 2024 | 1078 | 0.170 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 25 | 0.170 |
Why?
|
| Male | 20 | 2025 | 23409 | 0.170 |
Why?
|
| Antigens, CD | 1 | 2021 | 127 | 0.170 |
Why?
|
| Systems Biology | 1 | 2020 | 27 | 0.160 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 36 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 102 | 0.160 |
Why?
|
| Cell Communication | 2 | 2019 | 114 | 0.160 |
Why?
|
| Integrins | 1 | 2020 | 54 | 0.160 |
Why?
|
| Organ Specificity | 3 | 2018 | 141 | 0.160 |
Why?
|
| Recombination, Genetic | 1 | 2020 | 95 | 0.160 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 55 | 0.150 |
Why?
|
| Immunoglobulin G | 6 | 2007 | 259 | 0.150 |
Why?
|
| Disease Progression | 2 | 2019 | 667 | 0.150 |
Why?
|
| Mice, SCID | 4 | 2011 | 158 | 0.150 |
Why?
|
| NADP | 1 | 2019 | 37 | 0.150 |
Why?
|
| Interleukin-12 | 3 | 2010 | 46 | 0.150 |
Why?
|
| Antigens, CD20 | 1 | 2018 | 3 | 0.150 |
Why?
|
| Glucans | 1 | 2018 | 9 | 0.150 |
Why?
|
| Protozoan Vaccines | 1 | 2018 | 16 | 0.150 |
Why?
|
| Chitin | 1 | 2018 | 20 | 0.150 |
Why?
|
| Neuralgia | 1 | 2019 | 22 | 0.140 |
Why?
|
| Muramidase | 5 | 2004 | 30 | 0.140 |
Why?
|
| Coccidioides | 1 | 2018 | 55 | 0.140 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 54 | 0.140 |
Why?
|
| Genomics | 1 | 2020 | 293 | 0.140 |
Why?
|
| Spleen | 6 | 2016 | 204 | 0.140 |
Why?
|
| Receptors, Interferon | 2 | 2015 | 14 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2018 | 51 | 0.140 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 26 | 0.140 |
Why?
|
| Receptors, Peptide | 1 | 2017 | 24 | 0.140 |
Why?
|
| Amino Acid Sequence | 7 | 2012 | 1180 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 58 | 0.130 |
Why?
|
| Vaccination | 3 | 2017 | 355 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2018 | 368 | 0.130 |
Why?
|
| Aging | 2 | 2002 | 783 | 0.130 |
Why?
|
| Drug Design | 1 | 2018 | 186 | 0.120 |
Why?
|
| Microglia | 2 | 2021 | 208 | 0.120 |
Why?
|
| Immunity, Cellular | 3 | 2015 | 74 | 0.120 |
Why?
|
| Lymphocyte Count | 4 | 2007 | 46 | 0.120 |
Why?
|
| Chromones | 1 | 2016 | 53 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2016 | 91 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 21 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 74 | 0.120 |
Why?
|
| Vaccines, Attenuated | 1 | 2016 | 75 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2013 | 132 | 0.120 |
Why?
|
| Intestines | 1 | 2016 | 71 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2016 | 91 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 247 | 0.120 |
Why?
|
| Macrophages | 2 | 2011 | 529 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 36 | 0.110 |
Why?
|
| Clone Cells | 2 | 2007 | 50 | 0.110 |
Why?
|
| Portraits as Topic | 1 | 2015 | 2 | 0.110 |
Why?
|
| Phagocytosis | 1 | 2015 | 86 | 0.110 |
Why?
|
| Bacterial Proteins | 2 | 2010 | 595 | 0.110 |
Why?
|
| Sepsis | 1 | 2016 | 90 | 0.110 |
Why?
|
| Anniversaries and Special Events | 1 | 2015 | 6 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 167 | 0.110 |
Why?
|
| Kinetics | 2 | 2010 | 695 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 83 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 52 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2013 | 18 | 0.100 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2013 | 8 | 0.100 |
Why?
|
| Aged | 4 | 2025 | 8214 | 0.100 |
Why?
|
| Receptors, HIV | 1 | 2013 | 5 | 0.100 |
Why?
|
| Aluminum Hydroxide | 2 | 2004 | 8 | 0.100 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2013 | 11 | 0.100 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 224 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 72 | 0.100 |
Why?
|
| Aquaporin 4 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 94 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 1542 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2013 | 45 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 2 | 2013 | 209 | 0.090 |
Why?
|
| Immunoassay | 1 | 2012 | 74 | 0.090 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 28 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2010 | 462 | 0.090 |
Why?
|
| Time Factors | 4 | 2017 | 1857 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 587 | 0.090 |
Why?
|
| Receptors, IgE | 1 | 2011 | 22 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2011 | 19 | 0.090 |
Why?
|
| Brain Chemistry | 3 | 2012 | 141 | 0.090 |
Why?
|
| Antibodies, Blocking | 1 | 2011 | 11 | 0.090 |
Why?
|
| Asparaginase | 1 | 2011 | 5 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2005 | 74 | 0.090 |
Why?
|
| Axons | 1 | 2011 | 117 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2011 | 104 | 0.080 |
Why?
|
| Phagosomes | 1 | 2010 | 33 | 0.080 |
Why?
|
| Models, Animal | 1 | 2011 | 151 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1455 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 372 | 0.080 |
Why?
|
| Glycoproteins | 3 | 2005 | 125 | 0.080 |
Why?
|
| Endopeptidases | 2 | 2008 | 64 | 0.080 |
Why?
|
| Alleles | 3 | 2025 | 352 | 0.080 |
Why?
|
| Lung | 2 | 2010 | 492 | 0.080 |
Why?
|
| Butadienes | 1 | 2009 | 29 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 43 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2009 | 31 | 0.080 |
Why?
|
| Administration, Intranasal | 5 | 2009 | 89 | 0.080 |
Why?
|
| Nitriles | 1 | 2009 | 81 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2011 | 133 | 0.080 |
Why?
|
| Microwaves | 3 | 2014 | 29 | 0.070 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2008 | 4 | 0.070 |
Why?
|
| Contact Inhibition | 1 | 2008 | 4 | 0.070 |
Why?
|
| Acute Disease | 3 | 2005 | 155 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 161 | 0.070 |
Why?
|
| Guinea Pigs | 2 | 2007 | 143 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 159 | 0.070 |
Why?
|
| Vaginal Diseases | 1 | 2008 | 9 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 458 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 257 | 0.070 |
Why?
|
| Immunity, Innate | 2 | 2008 | 171 | 0.070 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 13 | 0.070 |
Why?
|
| DNA Replication | 1 | 2008 | 148 | 0.070 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2007 | 19 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 31 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 2016 | 91 | 0.060 |
Why?
|
| Hypersensitivity | 1 | 2006 | 32 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 174 | 0.060 |
Why?
|
| Age Factors | 2 | 2007 | 1154 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2009 | 561 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2003 | 25 | 0.060 |
Why?
|
| Allergens | 1 | 2006 | 65 | 0.060 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 48 | 0.060 |
Why?
|
| Immunologic Techniques | 1 | 2025 | 12 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 2 | 1996 | 17 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 256 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 27 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2025 | 206 | 0.060 |
Why?
|
| Vaccines, Synthetic | 2 | 2018 | 80 | 0.060 |
Why?
|
| Protein Interaction Mapping | 1 | 2025 | 65 | 0.050 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 2 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2025 | 139 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 2676 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2018 | 50 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2004 | 4 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 296 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 1996 | 92 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2025 | 508 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2003 | 456 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2004 | 43 | 0.050 |
Why?
|
| Myocardium | 2 | 2021 | 263 | 0.050 |
Why?
|
| Interleukin-5 | 2 | 2000 | 6 | 0.050 |
Why?
|
| Immune Sera | 1 | 2003 | 56 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 53 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2003 | 32 | 0.050 |
Why?
|
| Magnetics | 2 | 2012 | 43 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 26 | 0.050 |
Why?
|
| Prognosis | 1 | 2025 | 861 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 1067 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2006 | 76 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2002 | 8 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 79 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1285 | 0.050 |
Why?
|
| Wound Healing | 1 | 2003 | 88 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2001 | 32 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2001 | 109 | 0.050 |
Why?
|
| Middle Aged | 4 | 2025 | 12222 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 734 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 15 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 220 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2003 | 173 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2003 | 129 | 0.040 |
Why?
|
| Clonal Deletion | 1 | 2000 | 3 | 0.040 |
Why?
|
| Vaccines | 1 | 2002 | 65 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 1759 | 0.040 |
Why?
|
| Triterpenes | 1 | 2000 | 18 | 0.040 |
Why?
|
| Vagina | 2 | 2011 | 89 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2025 | 1546 | 0.040 |
Why?
|
| Glycosides | 1 | 2000 | 23 | 0.040 |
Why?
|
| Cell Death | 2 | 2012 | 278 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 719 | 0.040 |
Why?
|
| Mycobacterium Infections | 1 | 1999 | 16 | 0.040 |
Why?
|
| Protein Binding | 2 | 2018 | 1082 | 0.040 |
Why?
|
| Child | 2 | 2025 | 3443 | 0.040 |
Why?
|
| Arthritis, Reactive | 1 | 1998 | 1 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1998 | 5 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2000 | 300 | 0.040 |
Why?
|
| Antigens, Protozoan | 1 | 2018 | 74 | 0.040 |
Why?
|
| Lyme Disease | 1 | 1998 | 28 | 0.040 |
Why?
|
| Adult | 5 | 2025 | 13872 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1998 | 70 | 0.030 |
Why?
|
| Computational Biology | 2 | 2011 | 327 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1998 | 47 | 0.030 |
Why?
|
| Algorithms | 2 | 2017 | 509 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 68 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 205 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 277 | 0.030 |
Why?
|
| Immunity | 1 | 2016 | 61 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2015 | 5 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 13 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 20 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 239 | 0.030 |
Why?
|
| Spectrin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Synapsins | 1 | 2014 | 7 | 0.030 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2013 | 2 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chimera | 1 | 2013 | 18 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 24 | 0.030 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 14 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 19 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2013 | 39 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 34 | 0.020 |
Why?
|
| Immunity, Active | 1 | 2013 | 6 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2013 | 10 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 2013 | 70 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2018 | 460 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 1177 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 207 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 65 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1063 | 0.020 |
Why?
|
| Perforin | 1 | 2011 | 11 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 296 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.020 |
Why?
|
| Genetic Drift | 1 | 2011 | 6 | 0.020 |
Why?
|
| Directed Molecular Evolution | 1 | 2011 | 6 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 109 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2010 | 10 | 0.020 |
Why?
|
| Peptide Library | 1 | 2011 | 28 | 0.020 |
Why?
|
| Mannose-Binding Lectins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Organelles | 1 | 2010 | 20 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 1600 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2010 | 34 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 37 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2011 | 118 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 883 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 241 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 67 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 241 | 0.020 |
Why?
|
| Hela Cells | 1 | 2011 | 376 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2010 | 109 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 146 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 117 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 227 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 423 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 40 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2008 | 37 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 458 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 518 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 1070 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 220 | 0.020 |
Why?
|
| beta-Glucans | 1 | 2007 | 11 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 238 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 876 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1987 | 18 | 0.020 |
Why?
|
| Isoflavones | 1 | 2007 | 132 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2006 | 3 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2006 | 21 | 0.020 |
Why?
|
| Heart | 1 | 2007 | 184 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 69 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 139 | 0.010 |
Why?
|
| Plant Proteins | 1 | 2006 | 102 | 0.010 |
Why?
|
| Islets of Langerhans | 2 | 1996 | 16 | 0.010 |
Why?
|
| Mice, Inbred NOD | 2 | 1996 | 51 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 1028 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 2003 | 8 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 25 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 92 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 183 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 126 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 173 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2002 | 7 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2002 | 36 | 0.010 |
Why?
|
| Benzo(a)pyrene | 1 | 2003 | 128 | 0.010 |
Why?
|
| Influenza A virus | 1 | 2002 | 31 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 549 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 281 | 0.010 |
Why?
|
| DNA Damage | 1 | 2003 | 356 | 0.010 |
Why?
|
| Thymectomy | 1 | 2000 | 1 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2000 | 21 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2000 | 4 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2002 | 190 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2000 | 26 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2000 | 2 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 780 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 403 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2000 | 87 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 294 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 260 | 0.010 |
Why?
|
| Alum Compounds | 1 | 1999 | 1 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1999 | 73 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2000 | 192 | 0.010 |
Why?
|
| Stem Cells | 1 | 2000 | 152 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1998 | 6 | 0.010 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1998 | 2 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1998 | 52 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1998 | 87 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1998 | 57 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 561 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1996 | 16 | 0.010 |
Why?
|
| Leucovorin | 1 | 1990 | 5 | 0.000 |
Why?
|
| Vincristine | 1 | 1990 | 14 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 31 | 0.000 |
Why?
|
| Methotrexate | 1 | 1990 | 22 | 0.000 |
Why?
|
| Bleomycin | 1 | 1990 | 20 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1990 | 59 | 0.000 |
Why?
|
| Doxorubicin | 1 | 1990 | 97 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1990 | 154 | 0.000 |
Why?
|
| HLA-A2 Antigen | 1 | 1987 | 4 | 0.000 |
Why?
|
| HLA-B7 Antigen | 1 | 1987 | 2 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1987 | 9 | 0.000 |
Why?
|
| Adolescent | 1 | 1998 | 6081 | 0.000 |
Why?
|
| Transfection | 1 | 1987 | 532 | 0.000 |
Why?
|